This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hayes, C.
Right arrow Articles by Kurtin, P. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hayes, C.
Right arrow Articles by Kurtin, P. S.

PEDIATRICS Vol. 103 No. 3 March 1999, pp. 698

Effectiveness of RSV-IVIG in Premature Infants: Success in the Home

The first 20% of the full text of this article appears below.

To the Editor.

The efficacy and cost-effectiveness of respiratory syncytial virus immune globulin (RSV-IVIG) (RespiGam; MedImmune Inc, Gaithersburg, MD) as prophylaxis has been examined and challenged in many arenas. A letter to the editor, published in the February 1998 edition of Pediatrics, submitted data from the Children's Hospital and Health Center, San Diego and Sharp Mary Birch Women's Hospital neonatal intensive care unit. Their data described very poor compliance with subsequent RespiGam infusions and questionable benefit. SpectraCare's experience in the home care setting shows, quite distinctly, an increase in parental compliance, efficacy, and cost-effectiveness of respiratory syncytial virus (RSV) prophylaxis with RespiGam.

During the 1997-1998 RSV season (October 1997 to April 1998), 228 doses of RespiGam were administered by SpectraCare Home Health, Louisville agency, to 60 infants deemed eligible by the ordering neonatologist or pediatrician. The infants met Food and . . . [Full Text of this Article]